Related projects and initiatives
BioMedBridges is a joint effort of ten biomedical sciences research infrastructures on the ESFRI roadmap. Together, the project partners will develop the shared e-infrastructure—the technical bridges—to allow interoperability between data and services in the biological, medical, translational and clinical domains and thus strengthen biomedical resources in Europe.
p-medicine partner UDUS is a partner in this project.
CHIC focuses on the development of a suite of tools, services and infrastructures that will support the accessibility and reusability of multiscale mathematical and computational meta- and hypermodels of human diseases and normal human physiology. The CHIC tools, services, infrastructure and repositories will provide researchers and clinicians with a collaborative interface for exchanging knowledge and sharing work in an effective and standardized way. Cancer hypermodels, collaboratively developed by the consortium cancer modelers, will provide the framework and the testbed for the development of the CHIC technologies. p-medicine partners in CHIC: ICCS, EURICE, USAAR, FORTH, LUH, UOXF, Custodix, Philips, UCL
The European Advanced Translational Research Infrastructure (EATRIS) as an ESFRI-BMS infrastructure has expressed their support for and collaboration with p-medicine.
The 'European Clinical Research Infrastructures Network ECRIN', which is represented in the project through the partner UDUS, will support the effective and interoperable integration of p-medicine environment in an international clinical trials infrastructure and evaluate the usability and effectiveness of p-medicine tools used in a real clinical trial as part of the ECRIN clinical trial infrastructure.
The mission of ENCCA is to efficiently structure and enhance collaboration within the field of paediatric oncology in Europe. To achieve this mission ENCCA will limit knowledge fragmentation and improve communication channels. By bringing together existing informal paediatric and adolescent oncology clinical trial groups, ENCCA will create a sustainable "European Virtual Institute" for clinical and translational research in childhood and adolescent cancers. ENCCA will integrate all relevant stakeholders, their expertise and viewpoints to ensure that the project is all-encompassing while remaining patient-centred.
p-medicine partners in ENCCA: UCL, CAU, FORTH
The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. Françoise Meunier, EORTC Director General, is a member of the p-medicine International Ethical Committee.
The European Association for Predictive, Preventive and Personalised Medicine (EPMA) considers acute problems in medical sciences as well as the quality and management of medical services challenging health care systems in Europe and worldwide.
The Association is clearly structured in order to reach the possibly best coordination of the PPPM (Predictive, Preventive and Personalized Medicine)-related multifaceted activities over the whole Europe: there are national representatives in all 27 member countries of the European Union and the Associated-Countries (e.g. Israel, Serbia, etc.).
The goal of EURECA is to enable seamless, secure, scalable and consistent linkage of healthcare information residing in electronic health record (EHR) systems with information in clinical research information systems, such as clinical trials. Achieving semantic interoperability among EHR and clinical trial systems is at the core of the EURECA project, as it is the basis for enabling many of the software services and tools developed in the project. Eighteen partners are working together to build software services that help to securely interconnect the two systems. Successful linkage will deliver several benefits for patients, including early detection of patient safety issues and more efficient recruitment of eligible patients to trials. The systems will also enable long term follow up of patients. p-medicine partners Philips, USAAR, FORTH, Custodix, ecancer, UPM, LUH, UOXF and Fraunhofer IBMT and IAIS are also partners in this project.
iManageCancer - Empowering patients and strengthening self-management in cancer diseases
Chronic cancer treatment places new demands on patients and families to manage their own care. The iManageCancer project will support this challenge and provide a cancer disease self-management platform designed according to the specific needs of patient groups and focusing on the wellbeing of the cancer patient with special emphasis on psycho-emotional evaluation and self-motivated goals. The platform will be centred in a Personal Health Record that will exploit recent advances on Health Avatars for the individual cancer patient.
p-medicine partner FhG-IBMT is leading this project. FORTH, USAAR and Philips are, among others, participants in iManageCancer.
The INTEGRATE project aims to develop innovative infrastructures to enable data and knowledge sharing and to foster large-scale collaboration in biomedical research.
INTEGRATE flexible infrastructure components and tools will bring together heterogeneous multi-scale biomedical data generated through standard and novel technologies within post-genomic clinical trials. It will also provide a seamless link to existing research and clinical infrastructures, such as clinical trials management systems, eCRFs, and hospital EHRs.
p-medicine partners Philips, FORTH, Custodix and UPM are also partners in this project.
ITCC gathers 42 European Paediatric Oncology Departments with expertise in conducting early phase trials in children and adolescents, and 9 European research laboratories. The aim of this organisation is to develop novel therapies for the treatment of paediatric and adolescent cancers in cooperation with regulatory bodies, pharmaceutical enterprises, parents and patients.
Owing to the highly fragmented health systems in European countries, gaining access to a consistent record of individual citizens that involves cross-border activities is very difficult. MyHealthAvatar is a proof of concept for the digital representation of patient health status. It is designed as a lifetime companion for individual citizens that facilitates the collection of, and access to, long-term health-status information. This is extremely valuable for clinical decisions and offers a promising approach to acquire population data to support clinical research, leading to strengthened multidisciplinary research excellence in supporting innovative medical care.
p-medicine partners USAAR, FORTH, ICCS and LUH are also partners in MyHealthAvatar.
The Société Internationlae d’Oncologie Pédiatrique is also known under the English name International Society of Paediatric Oncology. Each year the Society runs a scientific meeting on all aspects of paediatric oncology. Besides the annual meetings, SIOP sponsors regional and continental meetings to promote the exchange of information and good practice in paediatric oncology all over the world.
The International BFM Study Group (I-BFM SG) is dedicated to promote both research and clinical care for children and adolescents with leukemia and lymphoma. A growing number of participating national study groups from meanwhile more than 30 countries world-wide collaborates in committees and associated working groups addressing important aspects of clinical and basic research in the field of leukemia and lymphoma occurring during childhood and adolescence.
VPH-Share will provide the essential services, as well as the computational infrastructure, for the sharing of clinical and research data and tools, facilitating the construction and operation of new VPH workflows, and collaborations between the members of the VPH community. p-medicine and VPH-Share will establish a close cooperation with regard to cloud computing throughout the duration of both projects in the respective work packages.
The Virtual Physiological Human Institute for Integrative Biomedical Research, in short VPH Institute, is an international non-profit organisation incorporated in Belgium, whose mission is to ensure that the Virtual Physiological Human is fully realised, universally adopted, and effectively used both in research and clinic. Since its establishment the VPH Institute has been collaborating with the community and the European Commission on different initiatives. p-medicine partners FORTH and ICCS are listed among the general members of the VPH Institute, while USAAR-HOM and UCL are supporting members.
is designed to foster, harmonise and integrate pan-European research in the field of patient-specific computer models for personalised and predictive healthcare and ICT-based tools for modelling and simulation of human physiology and disease-related processes. It is the intention of p-medicine to build up an interactive collaboration with the VPH NoE to harmonize tools, methods and services in interlinking with the VPH Toolkit. Different partners of p-medicine are also involved in this NoE.
Between ACGT, ContraCancrum and p-medicine a close interaction will take place, as several of the partners are also enrolled in these two European funded projects.
Between ACGT, ContraCancrum and p-medicine a close interaction will take place, as several of the partners are also enrolled in these European funded projects.
The EU funded Coordination and Support Action aims at analysing, improving and harmonising 'informed consent' across Europe. A close interaction will take place between Contract and p-medicine as several partners are active in both projects.
The transatlantic EC funded project 'TUMOR' aims at developing a European clinically oriented semantic-layered cancer digital model repository from existing EU projects that will be interoperable with the US grid enabled semantic-layered digital model repository platform at CViT.org (Center for the Development of a Virtual Tumor, Massachusetts General Hospital (MGH), Boston, USA) which is NIH/NCI-caGRID compatible. P-medicine will contribute to the population of the European cancer digital model repository through its VPH models.